US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Inspire Corporate Bond ETF

24.25

+0.12000.50%

Post-market: 24.250.00000.00%16:10 EST

Volume:50.16K

Turnover:1.21M

Market Cap:480.15M

PE:- -

High:24.25

Open:24.19

Low:24.11

Close:24.13

52wk High:24.85

52wk Low:22.84

Shares:19.80M

Float Shares:19.80M

Volume Ratio:0.75

T/O Rate:0.25%

Dividend:1.01

Dividend Rate:4.16%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Catch Up on Trump's Breakneck Critical-Minerals Drive -- WSJ

Unlocking the Potential of Multi-Indication Drugs: Can NLRP3 Give Rise to the Next Blockbuster?

Inspire Surpasses $4 Billion in Assets Under Management

THOMSON REUTERS

Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences

Talk About Range Anxiety -- Could Giant Cargo Ships Run on Batteries? -- WSJ

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings

Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CITIC SEC: Frequent Data Readouts from New and Existing Pipelines as MNCs Accelerate IBD Sector Expansion

Analyst Upgrade Boosts Shattuck On Confidence In Next-Gen Inflammatory Bowel Disease Therapy

Shattuck Labs to Participate in Upcoming December Investor Conferences

Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025

Absci to Participate in Upcoming Investor Conferences

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting

Press Release: Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

ACROBiosystems and Partners Conclude OrganoAsia 2025

Press Release: Spyre Therapeutics Announces Grants of Inducement Awards

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IBD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","market":"US","secType":"STK","nameCN":"Inspire Corporate Bond ETF","latestPrice":24.25,"timestamp":1770411600000,"preClose":24.13,"halted":0,"volume":50156,"hourTrading":{"tag":"盘后","latestPrice":24.25,"preClose":24.25,"latestTime":"16:10 EST","volume":10,"amount":242.5,"timestamp":1770412204838,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.004973062577704144,"floatShares":19800000,"shares":19800000,"eps":0,"marketStatus":"Market Closed","change":0.12,"latestTime":"02-06 16:00:00 EST","open":24.19,"high":24.25,"low":24.1101,"amount":1211667.5269,"amplitude":0.005798,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":24.13,"sharesOutstanding":19800000,"nav":24.13,"aum":477872152.99,"dividendRate":0.041625,"bidAskSpread":0.001804,"postHourTrading":{"tag":"盘后","latestPrice":24.25,"preClose":24.25,"latestTime":"16:10 EST","volume":10,"amount":242.5,"timestamp":1770412204838,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7461580814147161},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","floatShares":19800000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.7461580814147161,"shares":19800000,"dividePrice":1.0094,"high":24.25,"amplitude":0.005798,"preClose":24.13,"low":24.1101,"week52Low":22.84,"pbRate":"--","week52High":24.85,"institutionHeld":0,"latestPrice":24.25,"eps":0,"divideRate":0.041625,"volume":50156,"delay":0,"ttmEps":0,"open":24.19,"prevYearClose":24.2,"prevWeekClose":24.15,"prevMonthClose":24.15,"prevQuarterClose":24.2,"fiveDayClose":24.15,"twentyDayClose":24.14,"sixtyDayClose":24.11},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBD\",params:#limit:5,,,undefined,":[{"date":"2026-01-27","symbol":"IBD","amount":0.0592,"announcedDate":"2026-01-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-27","defaultRemindTime":1769524200000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-02","payableDate":"2026-01-27","currency":"USD","dateTimestamp":1769490000000,"payDate":"2026-02-02"},{"date":"2025-12-17","symbol":"IBD","amount":0.121,"announcedDate":"2025-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-17","defaultRemindTime":1765981800000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-17","currency":"USD","dateTimestamp":1765947600000,"payDate":"2025-12-24"},{"date":"2025-11-21","symbol":"IBD","amount":0.0729,"announcedDate":"2025-11-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-11-21","defaultRemindTime":1763735400000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-26","payableDate":"2025-11-21","currency":"USD","dateTimestamp":1763701200000,"payDate":"2025-11-26"},{"date":"2025-10-28","symbol":"IBD","amount":0.0824,"announcedDate":"2025-10-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-10-28","defaultRemindTime":1761658200000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-03","payableDate":"2025-10-28","currency":"USD","dateTimestamp":1761624000000,"payDate":"2025-11-03"},{"date":"2025-09-26","symbol":"IBD","amount":0.0899,"announcedDate":"2025-09-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-26","defaultRemindTime":1758893400000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-01","payableDate":"2025-09-26","currency":"USD","dateTimestamp":1758859200000,"payDate":"2025-10-01"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBD\",market:\"US\",,,undefined,":[{"executeDate":"2017-08-16","recordDate":"2017-08-18","paymentDate":"2017-08-23","value":0.0405,"currency":"USD"},{"executeDate":"2017-09-18","recordDate":"2017-09-19","paymentDate":"2017-09-25","value":0.0292,"currency":"USD"},{"executeDate":"2017-10-16","recordDate":"2017-10-17","paymentDate":"2017-10-23","value":0.0347,"currency":"USD"},{"executeDate":"2017-11-16","recordDate":"2017-11-17","paymentDate":"2017-11-28","value":0.0389,"currency":"USD"},{"executeDate":"2018-01-29","recordDate":"2018-01-30","paymentDate":"2018-02-05","value":0.0269,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609674309","title":"Catch Up on Trump's Breakneck Critical-Minerals Drive -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2609674309","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609674309?lang=en_us&edition=fundamental","pubTime":"2026-02-05 22:25","pubTimestamp":1770301500,"startTime":"0","endTime":"0","summary":"This is an edition of the WSJ Climate & Energy newsletter, a weekly must-read of news, analysis and exclusive data focused on the intersection of business, money and climate, with coverage from across Dow Jones. If you're not subscribed, sign up here.This week brought a blizzard of news about the Trump administration's drive to counter China's control over raw materials that go into everything from electric-vehicle batteries to jet fighters. The strategy looks increasingly like China's own. Here's what to know.Commodities trading houses signed up to provide metal, and companies including Boeing and gas-turbine maker GE Vernova endorsed the project. Companies using the reserve will determine which minerals it stores, choosing from a government list , said a spokesman for the U.S. Export-Import Bank. The agency is providing a $10 billion loan, topped up with roughly $1.67 billion of private capital.The deals \"represent how we are investing in the long-run success of American technology a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4109","MTX","IBD"],"gpt_icon":0},{"id":"1153894846","title":"Unlocking the Potential of Multi-Indication Drugs: Can NLRP3 Give Rise to the Next Blockbuster?","url":"https://stock-news.laohu8.com/highlight/detail?id=1153894846","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153894846?lang=en_us&edition=fundamental","pubTime":"2026-02-05 16:42","pubTimestamp":1770280959,"startTime":"0","endTime":"0","summary":"Strategic decisions in biopharmaceutical pipeline development often involve a multidimensional balance of innovation, feasibility, and return on investment. Among these, the \"pipeline in a drug\"...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","PD","AD","IBD","BK4132","LU1169590202.USD","LU1169589451.USD","BK4023","CNS","BBB"],"gpt_icon":0},{"id":"2607741841","title":"Inspire Surpasses $4 Billion in Assets Under Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2607741841","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607741841?lang=en_us&edition=fundamental","pubTime":"2026-01-29 02:05","pubTimestamp":1769623559,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nTUA8K8LFJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBD","RISN","BLES","WWJD","GLRY","FDLS","ISMD","BIBL","PTL"],"gpt_icon":0},{"id":"2603999387","title":"Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2603999387","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603999387?lang=en_us&edition=fundamental","pubTime":"2026-01-16 21:30","pubTimestamp":1768570200,"startTime":"0","endTime":"0","summary":"PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative Colitis Carlsbad, CA, Jan.  16, 2026  (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/16/3220317/0/en/Palisade-Bio-Announces-Two-Abstracts-Selected-for-Poster-Presentations-at-Leading-Global-Inflammatory-Bowel-Disease-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBD"],"gpt_icon":0},{"id":"2603985053","title":"Talk About Range Anxiety -- Could Giant Cargo Ships Run on Batteries? -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2603985053","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603985053?lang=en_us&edition=fundamental","pubTime":"2026-01-15 22:25","pubTimestamp":1768487100,"startTime":"0","endTime":"0","summary":"This is an edition of the WSJ Climate & Energy newsletter, a weekly must-read of news, analysis and exclusive data focused on the intersection of business, money and climate, with coverage from across Dow Jones. If you're not subscribed, sign up here.Any readers considering a life on the high seas can assess their career options at maritime-zone.com. It lists more than 30 openings for the position of wiper. You'd make about $1,500 a month.\"The job is to wipe oil that's leaking out of an engine,\" says marine engineer turned entrepreneur Steven Henderson. \"Working on a ship in the middle of the ocean is brutal.\". Unromantic about what life is like for most seafarers, Henderson dreams of making automated battery-powered container ships with no crew at all. For now, his company makes big batteries. Fleetzero recently opened a factory in Houston and just raised $43 million from investors including shipping giant Maersk to expand its manufacturing capacity.Counterintuitively, electrifying lo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBD"],"gpt_icon":0},{"id":"2603686974","title":"Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2603686974","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603686974?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:00","pubTimestamp":1768305600,"startTime":"0","endTime":"0","summary":"KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027  KT-579 Phase 1 HV clinical trial expect","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/13/3217633/0/en/Kymera-Therapeutics-Outlines-Key-2026-Objectives-and-Strategy-to-Advance-Industry-Leading-Portfolio-of-Oral-Immunology-Programs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BP","BK4096","AD","LU1829250122.USD","BK4139","EASI","LU0162691827.USD","LU0320765646.SGD","IBD","PN","RA","LU1162221912.USD","BK4201","BK4585","LU0072461881.USD","BK4132","BK4588"],"gpt_icon":0},{"id":"2602543556","title":"Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543556","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543556?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:30","pubTimestamp":1768224600,"startTime":"0","endTime":"0","summary":"Bitopertin was awarded the Commissioner’s National Priority Review Voucher (CNPV) and NDA is currently under FDA reviewUpdated data from the Phase 2 study of DISC-0974 in patients with myelofibrosis (","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216904/0/en/Disc-Medicine-Highlights-Recent-Achievements-and-Key-Business-Objectives-and-Milestones-for-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCD","LU0053671581.USD","BK4139","IBD","IRON"],"gpt_icon":0},{"id":"2592943946","title":"Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943946","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592943946?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:05","pubTimestamp":1766005500,"startTime":"0","endTime":"0","summary":"Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of Scientific","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/17/3207315/0/en/Abivax-Announces-Acceptance-of-22-Abstracts-Evaluating-Obefazimod-in-Inflammatory-Bowel-Disease-at-ECCO-2026-Featuring-an-Oral-Presentation-on-Preclinical-Anti-Fibrotic-Findings.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CD","BK4023","BK4116","BK4157","BMI","IBD"],"gpt_icon":0},{"id":"2591524624","title":"Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2591524624","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591524624?lang=en_us&edition=fundamental","pubTime":"2025-12-16 05:15","pubTimestamp":1765833300,"startTime":"0","endTime":"0","summary":"AUSTIN, TX and DURHAM, NC, Dec.  15, 2025  (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of no","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/15/3205857/0/en/Shattuck-Labs-Inc-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBD","STTK","BK4139"],"gpt_icon":0},{"id":"1169817402","title":"CITIC SEC: Frequent Data Readouts from New and Existing Pipelines as MNCs Accelerate IBD Sector Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=1169817402","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169817402?lang=en_us&edition=fundamental","pubTime":"2025-12-11 09:46","pubTimestamp":1765417598,"startTime":"0","endTime":"0","summary":"CITIC SEC released a research report highlighting that inflammatory bowel disease (IBD), a challenging autoimmune disorder, presents significant unmet clinical needs and vast market potential....","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0405327148.USD","BK0028","LU1064131003.USD","BK0276","LU0405327494.USD","BK1516","LU2289578879.USD","BK1564","BK0196","BK1521","LU1064130708.USD","LU1997245094.SGD","LU2148510915.USD","LU1997245177.USD","BK0183","LU2495084118.USD","IBD","LU1720050803.USD","LU1997244956.HKD","BK1147","LU1794554557.SGD","LU1655091616.SGD","600030","06030","BK0012","LU1255011170.USD","LU1328615791.USD","BK0188"],"gpt_icon":0},{"id":"2588037087","title":"Analyst Upgrade Boosts Shattuck On Confidence In Next-Gen Inflammatory Bowel Disease Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2588037087","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588037087?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:33","pubTimestamp":1764624780,"startTime":"0","endTime":"0","summary":"HC Wainwright upgrades Shattuck Labs on confidence in SL-325, a DR3 antibody aiming for stronger, durable IBD treatment amid TL1A concerns.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/01/Doctor-In-A-White-Coat-Hands-Holding-Sto.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/01/Doctor-In-A-White-Coat-Hands-Holding-Sto.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/upgrades/25/12/49148950/bowel-disease-therapy-analyst-upgrade-boosts-shattuck","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/upgrades/25/12/49148950/bowel-disease-therapy-analyst-upgrade-boosts-shattuck","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LU1057294990.SGD","LU2023250504.SGD","LU0006306889.USD","IE00BJT1NW94.SGD","LU1066053197.SGD","LU1989771016.USD","BK4533","SG9999014542.SGD","LU0965509283.SGD","SG9999014575.USD","LU0289739699.SGD","LU1037948897.HKD","LU2361045086.USD","IE00BLSP4239.USD","BK4139","BK4116","LU1934455277.USD","BK4516","IBD","LU1989772923.USD","BK4534","LU1023059063.AUD","LU1037948541.HKD","LU1929549753.HKD","BK4007","LU2361044865.SGD","LU1066051498.USD","LU0965509010.AUD","LU1571399168.USD","SG9999001440.SGD","SGXZ57979304.SGD","IE00BFTCPJ56.SGD","IE000M9KFDE8.USD","LU0208291251.USD","LU1989772840.SGD","SG9999001176.USD","MRK","LU1093756168.USD","LU0234572021.USD","STTK","CD","LU2468319806.SGD","LU2089984988.USD","LU1093756325.SGD","LU0070302665.USD","LU0058720904.USD","LU0965508806.USD","LU1974910355.USD","LU0265550359.USD","LU0861579265.USD"],"gpt_icon":0},{"id":"2584348671","title":"Shattuck Labs to Participate in Upcoming December Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2584348671","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584348671?lang=en_us&edition=fundamental","pubTime":"2025-11-20 21:00","pubTimestamp":1763643600,"startTime":"0","endTime":"0","summary":"AUSTIN, TX and DURHAM, NC, Nov.  20, 2025  (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of no","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/20/3191843/0/en/Shattuck-Labs-to-Participate-in-Upcoming-December-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STTK","IBD","BK4139"],"gpt_icon":0},{"id":"2579131781","title":"Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2579131781","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579131781?lang=en_us&edition=fundamental","pubTime":"2025-10-30 04:05","pubTimestamp":1761768300,"startTime":"0","endTime":"0","summary":"VANCOUVER, Wash. and NEW YORK, Oct.  29, 2025  (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the co","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176853/0/en/Absci-to-Report-Business-Updates-and-Third-Quarter-2025-Financial-and-Operating-Results-on-November-12-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4543","AI","BK4587","BK4551","BK4528","BK4023","IBD"],"gpt_icon":0},{"id":"2578645714","title":"Absci to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2578645714","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578645714?lang=en_us&edition=fundamental","pubTime":"2025-10-27 20:00","pubTimestamp":1761566400,"startTime":"0","endTime":"0","summary":"VANCOUVER, Wash. and NEW YORK, Oct.  27, 2025  (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today anno","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/27/3174476/0/en/Absci-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4587","IBD","BK4551","BK4528","BK4543","BK4581","LABU","XLV","AI","BK4023","BK4588","XBI"],"gpt_icon":0},{"id":"2578964388","title":"Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2578964388","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578964388?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:00","pubTimestamp":1761562800,"startTime":"0","endTime":"0","summary":"KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to appro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/27/3174428/0/en/Kymera-Therapeutics-Presents-New-Preclinical-Data-for-KT-579-a-First-in-Class-Oral-IRF5-Degrader-at-the-American-College-of-Rheumatology-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4117","RA","BK4115","IBD","KT","ACR","LU0541501648.USD","BK4107","KYMR","AFG","BK4110","LU0541502299.USD","BK4139"],"gpt_icon":0},{"id":"2575756018","title":"Press Release: Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2575756018","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575756018?lang=en_us&edition=fundamental","pubTime":"2025-10-16 04:15","pubTimestamp":1760559300,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Oct. 15, 2025  -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease  and other immune-mediated diseases, today announced the closing of its previously announced underwritten public offering of 17,094,594 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 2,229,729 additional shares, at a public offering price per share of $18.50. The gross proceeds to Spyre from the offering were approximately $316.2 million before deducting underwriting discounts and commissions and other offering expenses payable by Spyre.Jefferies LLC, TD Securities  LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated acted as the joint book-running managers for the offering. Wedbush Securities Inc. acted as lead manager for the offering.Spyre Therapeutics is a clini","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","IBD","USA","BK4539","SYRE","BK4007"],"gpt_icon":0},{"id":"2575375784","title":"Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2575375784","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575375784?lang=en_us&edition=fundamental","pubTime":"2025-10-15 20:00","pubTimestamp":1760529600,"startTime":"0","endTime":"0","summary":"Webinar on December 11 to feature leading KOLs in dermatology and hair loss alongside Absci leadership Phase 1/2a trial now expected to begin in December 2025, ahead of prior guidance  VANCOUVER, Wash","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/15/3167012/0/en/Absci-to-Host-KOL-Seminar-on-ABS-201-Androgenetic-Alopecia-Program-on-December-11-2025-Announces-Accelerated-Initiation-of-Phase-1-2a-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IBD","HST","BK4588","BK4218","KOL","BK4181"],"gpt_icon":0},{"id":"2575528054","title":"Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2575528054","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575528054?lang=en_us&edition=fundamental","pubTime":"2025-10-14 04:01","pubTimestamp":1760385660,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Oct.  13, 2025  (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineer","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/13/3165784/0/en/Spyre-Therapeutics-Announces-Proposed-Public-Offering-of-its-Common-Stock-and-Pre-Funded-Warrants.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBD","BK4007","BK4539","USA","LENZ","BK4139"],"gpt_icon":0},{"id":"2574143601","title":"ACROBiosystems and Partners Conclude OrganoAsia 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2574143601","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574143601?lang=en_us&edition=fundamental","pubTime":"2025-10-10 09:21","pubTimestamp":1760059260,"startTime":"0","endTime":"0","summary":"- Leading Scientists from China, Japan and South Korea Convene to Drive Organoid Research and Commercialization   TOKYO, Oct. 10, 2025 /PRNewswire/ -- ACROBiosystems, together with Leica Biosystems, Molecular Devices, and Leica Microsystems, hosted the OrganoAsia 2025-The Frontier of Organoid Science in Beijing. The hybrid-format conference featured an in-person opening session alongside a live online stream, drawing more than 500 experts and researchers—primarily from China, Japan, and South Korea, with additional global attendees—to examine recent progress and future directions for organoid technology in precision medicine, drug discovery, and regenerative medicine.","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2780465/image_5024610_12421859.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2780465/image_5024610_12421859.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/acrobiosystems-and-partners-conclude-organoasia-2025-302580426.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEA.AU","IBD","BK7004"],"gpt_icon":0},{"id":"2572633851","title":"Press Release: Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2572633851","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572633851?lang=en_us&edition=fundamental","pubTime":"2025-10-04 04:05","pubTimestamp":1759521900,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Oct. 03, 2025  -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 42,500 shares of common stock of Spyre to three non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended . The stock options were approved on October 1, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635.Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease  and other immune-mediated disease products by combining best-in-cla","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","NQmain","LENZ","IBD","BK4007","SYRE"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":32,"code":"91000000","status":"200"}]}}